COVID-19: Vaccines and Therapeutics
The Centers for Medicare & Medicaid Services (CMS) today issued a memorandum confirming that it will not enforce its vaccine mandate while it remains enjoined by the Missouri and Louisiana district courts.
The Centers for Medicare & Medicaid Services began requiring state Medicaid programs to cover counseling visits at which health care providers talk with families about COVID-19 vaccination for their children
A federal district court in Louisiana late yesterday issued a preliminary injunction placing a temporary hold on enforcement of the Centers for Medicare & Medicaid Services vaccine mandate for health care facilities in all states, except the 10 already covered by the Missouri district court’s…
The Food and Drug Administration’s Antimicrobial Drugs Advisory Committee late yesterday voted to recommend an emergency use authorization for Merck’s investigational oral antiviral COVID-19 medicine. The drug, molnupiravir, is meant for the treatment of mild-to-moderate COVID-19 in at-risk adults.
Pfizer yesterday asked the Food and Drug Administration to expand the emergency use authorization for its COVID-19 vaccine booster to include youth aged 16 and 17.
A federal district court in Louisiana late yesterday issued a preliminary injunction placing a temporary hold on enforcement of the Centers for Medicare & Medicaid Services vaccine mandate for health care facilities in all states, except the 10 already covered by the Missouri district court’s…
AHA's letter of support to Reps. Tom O’Halleran (D-AZ), David McKinley (R-WV), Lucille Roybal-Allard (D-CA), and David Joyce R-OH) for the Student Assisted Vaccination Effort Act (H.R. 5699).
The U.S. District Court for the Eastern District of Missouri today granted a preliminary injunction preventing the Centers for Medicare & Medicaid Services from enforcing its vaccine mandate rule in Alaska, Arkansas, Iowa, Kansas, Missouri, Nebraska, New Hampshire, North Dakota, South Dakota…
A two-dose series of the Pfizer-BioNTech COVID-19 vaccine was 100% effective against COVID-19 in 12-14 year olds more than four months after the second dose in the companies’ phase 3 clinical trial, Pfizer and BioNTech announced.
Centers for Disease Control and Prevention Director Rochelle Walensky, M.D., expanded eligibility for COVID-19 booster shots to include all adults aged 18 and older who received a second dose of the Pfizer or Moderna vaccine at least six months ago, as recommended by the agency’s Advisory Committee…